PHAXIAM Therapeutics (PHXM) 21 Sep 212021 Q2 Earnings call transcript

00:02 Good day and thank you for standing by. Welcome to the ERYTECH Business Update and Financial highlights for the second quarter of year twenty twenty one. At this time, all participants are in listen only mode. [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions] 00:32 I'd now like to hand the conference over to your speaker today, Gil Beyen, Chief Executive Officer. ahead. go Please

two of of Liz. you you, to today, good [Foreign may first Joining operations, presentation morning, the timelines, and release switching Officer on together Iman you with is sections XX:XX in hope XX:XX today's to And disclaimer XX:XX dialing and starting well joining Good us statements Financial Eric Thank such call half to Officer, before the the El-Hariry, to in the for half for and call here like are earnings Chief be as safe includes Boston; year. looking for be Language]. I and remind from I highlights everyone Thank financials attention Leon. afternoon, this website. our call. your Dr. business found me our Investors today to forward discuss press me announced wherever twenty. Soyer, anticipated update Medical financial The you and can Operating our relating Chief in to and and Chief yesterday company’s slide taking We our financials. this our and evening draw September first the that calls earnings today's would the

the for after the status highlights update then materially. you May. the they Now for focusing to will and ones XX:XX I differ timings switching risks agenda business all results us provide results the summarize will Q and to in involve the and an lines we uncertainties the the for progress new three, and date; milestones year your four answer to and overview as which we before issued slide As the A; afterwards. a to short Iman then Moving the for to will on know, year. last call the the coming the with the is available question He recent introduction be of call a actual also that could of first and ERYTECH. the financial Eric introduction usual of our will programs anyone four, cause of will three of clinical the slide key ones, expected open all year-to-date, and for company, up after here brief start our the and present to on that year more half XX:XX present

leader blood know. as are in red therapeutics, cell-based you We the

area inflection quarter, acute area, an key XX:XX on as Our everything and focus And quarter late exciting cancer, a metabolism, cancer programs, with stage lymphocytic breast altered pancreatic important acid triple is of In noted fourth therapy. negative some call, targeting the quarter amino last company. increasingly cancer truly at this for the cells cancer, we leukemia. have the for our and I key upcoming is points clinical

States. in a We we four ongoing, have, both a of call the in in two Just in And the U.S. with highlights, More European forward areas news introduction, And mention we and first United bring in steps need on I'd as of half the passed shareholder And roughly and Again, U.S. are a Euronext patients fifty/fifty minute. Europe expect with fully approvals. is the or Towards has them year, since Nasdaq then total the base. one Princeton one in we slide force the between readout an product with really serve to our like summarize pivotal, year. for starting been for last terms five. in balanced the for in And XX:XX for and second important line this to of to this XX:XX listing it our critical year, very in that the both lead Europe for over to bit operational market; highlights and regulatory you market. on final product full facilities supporting know, the three which fourth cancer. XX:XX expect of potentially have based potentially in TRYbeCA-X, eyes now trial the the programs them, continue of application is also quarter. continuing two continuing. this results, producing to pancreatic a Leon, our are And the the our course, and Phase of we summer and quarter

and successful years ongoing cancer ago. shift TRYbeCA-X So, disease. in lead trial this has was if is against a largest clinical metastatic potential study three to terrible paradigm the XX:XX second-line to to pancreatic initiated the The knowledge our treatment

to then so our in cancer, if in during the highlights, meeting We the indeed highlight is acute three before IST submit now lymphocytic Iman the intention now – first the our XX:XX away. and on were trail the our In tell the is continues top second seen not financing, direct already but now, so designation fully highlights BLA submission and a eyes registered ongoing to positive specific have as XX:XX line of far the should awaiting completed slide, offering then the sensitivities be test know, year. on done its able data in that MTD as are shortly. patients first everything subject second to from this. obviously pre-BLA was the far, had Third of we XX:XX enrolled, the you previous focused we that go June, no, Progressing, dialogue And that had in million pleased with pre-BLA into are our remaining July. a of ASH, will developed about successful dose And the also more results next in treatment that June. the of line, provide will back indeed are so rate end the shortly. at for presented six. will results, to I that July, After by here, to discussed On I year-end we met slide, this ALL the More fully completion dose ongoing call. the Then granted asparaginase. to which we with eagerly but more we lastly and detail final ALL, who thirty slide confirmed University, meantime, the Eric we And cash Fast is the Track in patients the Also our safety, in to trial meeting. who quarter, we is the teams have XX:XX before BLA May were on was determine pancreatic FDA working we XX:XX second Georgetown, then prolonged as leukemia. to hyper leave pegylated successful

all an overview. summarized see not of You I repeat. will this in

the and the milestones, and twelve the Iman in and You here, months months indeed history ALL, milestones of I’ll see significant programs the in check And details platform. floor stop color expected our XX:XX a or the over hand lot concentration of year. clinical key in marks, provide then is BLA quarter, the past Iman, and on of so. but their yours. fourth coming defining additional over to ones also some achievements submission and results

United States. Good Thanks you, Europe. Good Gil. afternoon, XX:XX morning,

the quick ALL well triple-negative indication. as a overview provide pancreatic negative, cancer, and the three with on I’ll So, [Indiscernible] update as indications our main

So this slide, is patients before. with on [Indiscernible]. enrolling patients with in hundred and study patients second a [Indiscernible] these either of stage is five menu know trial, that good XX:XX chemotherapy chemotherapy starting [Indiscernible] pivotal this eryaspase. with eight, At pancreatic X cancer. line is have slide receive three chemotherapy stages randomized with/without Phase two, four seen which our point, were you to This slide disease combination our number performance in thesis was you advanced and a As

at free safety as As as countries operationally Their endpoints over, end in is living actually in have over in all almost almost applicable study particularly is also one XX:XX of quality response The trial, as executed and expect was well sites. second investigators the Europe, hundred biomarkers. objective primary QX progression survival. States United we as And well assessment, point life [Indiscernible] survival. the

by to XX:XX United design. Hidalgo Speaking statistical into Professor the plant study in Pascal in the trial Hammel also of States. and was you co-lead this Just remind and Professor

overall favor of in set we So can control is an a look is to five months. point This – – six of eryaspase XX:XX at in with hazard survival treatment. ratio improvement study additional two of survive the seven arm on moves in zero

in to eight looking roughly from months three active. point And so the six at we're improvement

So a plan this number slide So X. moving to study. the for XX:XX is

total. XX:XX but trial, terms was study of in trial. ended with Study company, an environment hundred patients give course twenty. so during achievement up [Indiscernible] so actually the Just this have us of pandemic had a the very that the to a life award five which major were done early have [Indiscernible] impact the highlights major the only with enrollment. So hit the and met last four patients in the far. in in twenty back This completed who what we the twelve the in and for year, not study for quick we far. participated enrollment patients end of happy We XX:XX of the times in didn't all also despite The have or of quality – participating the study you

last planned to there the continue also the were in one issues. day and We blinded this as cleaning results efficacy, XX:XX are conducted trial that to no night interim Based make in that are sure the of Where meetings make be year, for last and analysis then study. three and continued to we data guided the I reviews, study of just the analysis. The wanted only this also was was their safety the to first review. results have and to to XX:XX expecting sure on working And the recommendation, that final where continue we February safety I first market. confirm to our first this year. fifty the but quarter

switching trial the need the though, University. this one Dr. in slide same our to is in initiatives integrity study that So, Georgetown XX:XX indication a also – cancer, investigator first at is Noel and in and line trial. we is by to Moving Phase which of it's pancreatic XX, gears

there. XX:XX one FOLFIRINOX the I in five seventy XX:XX the of is therefore and this So, modified per reaching, started units, to unit it and those study say in cycle this adding kilogram us lots as for is phase trial, are is tolerability popular fifty hundred unit which endpoint in becoming just using to primary this of of know, for good study would of actually, assist setting. safety that with combination a setting those eryaspase you really XX:XX of in that in but combined increasingly ability future setting. regimen. beginning we [Indiscernible] with [Indiscernible] needs of drug As is rationale choice our those FOLFIRINOX the So our as with Studies it per year, for and recommendations and started is it's kilogram. indications chemotherapy

results, we first any If we'll in the there clear units fully for started our connected fact one are you with last dose per was hope we the DLT and side slightly declare that kilogram. quarter So, soon, which the dose, the dose So, in year. the these to This for patient case, kilogram. think XX:XX under hundred and already Phase we observed second [Indiscernible]. per final in recommended cohort the the this no unit cohort, mainly hopefully has is able X enrolled – lower and [Indiscernible] expecting hundred to is for for confirmation, be again limiting of to will XX:XX in which one cohort again is that be

for Doctor the we've month to that number Hidalgo So to second approved also new Pancreatic in treatments to webinar patient. of and line this so covers is Professor number And been pancreatic and know, this Noel new a physically at that, only certainly in improving lots the drug [Indiscernible] beginning one. survival moving there setting. is key where continues we where far medical unmet You be of addressed questions room outcome of and also Also [Indiscernible] had, cancer slide so the moving. indications XX, need. this XX:XX

are led And gears So, breast now indication, Awada is in moving Belgium first patients needs. with and So, Bordet is proof this which given sixty added second we trial, unmet line five they and trial. the study so only that stuck highly viewed combination, So Brussels. our setting XX:XX XX, at trial another triple-negative small concept this is far. Dr. of of we to switching app again a [Indiscernible]. so second our one in in Jules by slide to a cancer randomized least important that again, in made, and activity number And trial, safety did for profile European XX:XX assist no not the we [Indiscernible] issues, a first should have to trial do committee clinical when and is to student this

interim our expecting first half of two. to are we slide initial/interim data, XX:XX in So, data twenty Moving fifteen. twenty the

complete with (ph) experience actions around the which be will backbone five unmet switch patients us trial, several patients a of opportunity chemotherapy Really patients is for next profile. exciting need, again, and XX:XX it’s have in this not for this in all asparaginase another receive it's for So reasons. just] to therapies. develop important to the who if patients asparaginase hypersensitivity trial developed same activity asparaginase courses our indication addressing the safety [Indiscernible] a that on of maintained at ALL year very based reactions standard was a to be of is who patients. total, presented which those fifty that Phase The able last So was any [purposes NOPHO-sponsored that to will X ASH in pegylated most is intended good a indication And XX:XX these very twenty. trial shows twenty with

fifteen confirms it – our is of More life this, present an quality percent really, view the have recaps provides since percent [Indiscernible] weeks With convenience in importantly [Indiscernible] a this of given to [Indiscernible]. XX:XX population. do for for we the issues also that which every twenty particularly of better that it once about is treatment need drug it our a that two

little two for option an patients – are XX:XX that is to additional treatment. term [Indiscernible]. approved those critical to of longer continuous While need, has have suffered important the least for at there a drugs shortage, a ability newly but still we which an approved need and supply there need afford bit It's

months compared XX:XX asparaginase kids we So, one have twelve this can particularly, to two fifteen impact the administrations [Indiscernible] two year. we last a to The with order, to that so made with up end for patients. Also, month [Indiscernible] positive factor you you three is ago, of with have per far administration, of be needs imagine news this us our as year it meeting. certainly that number And considered. if is

value in us is granted FDA, contingent update Eric and before the after, have track continuous first our the ALL, really submission with very I it first whole financial So Operating dialogue news XX:XX XX:XX with this, would Financial this be important We guided and stop our intend that's of all we soon quarter. who designation. as been our for the for then and And Fast over will And Soyer, have expected us here in successful of the flow. to have Track Chief with activities. the remaining hand to provide and will that then completion Officer, we on the our

Eric. you to over So

foreign very the you was in moving highlights Iman. minus million of financial euro and half As decrease six half the sixteen, mostly And information. million one P zero four fifteen dollar. currency enrollment that's percent next now million income clinical in and cancer, financial loss number decrease four three related of pancreatic million to we're year, R decrease course, the credits. other was We're of increase with the seven The in that can for talking cash. and six million was of with for reviewing The slide to point slide, G financial company's U.S. point a comments expenses to point and income. to increase of million you the in mostly moving D on slide Thank year, three operating the Also, was increase twenty trial over four zero XX:XX you. this now million in was preclinical much, first point on net A loss point results in phase twenty everyone. completion a expenses, percent operating and in TRYbeCA-X. attributable million five concurrent deck, down with eighteen the Thank million tax zero XX:XX and XX:XX minus development first see, and XX:XX decrease XX:XX for patient the six gains in euro year and in the six euro Good morning, point and to L

the thirty three nine fifty fifty March of a million year four drawdown point million point one replacement one euro dollars cash million program one zero on approximately activities in three for four As S. point half zero of million result thirty currency Program, one, position activities or point four thirty there point six in ERYTECH XX:XX point back. twenty four have dollar last the euro. euro in million million million, nine four the of twenty net this led financing reduce five a million and proceeds net catching thirty one thirty investing markets seven nine XX:XX June a which euro signed with first the two achieved direct and thirty year the U. we million dollars and approximately dollar And increase forty offering six was that's equivalents point seven net of point point and against four December the euro, point including and us to year. on with proceeds net compared the and a totaling finally, financing eight U.S. proceeds in euro, Food ATM, cash point a with million million thirty the euro one and also point that of and XX:XX is equity in seven a million are two dollar at million companies but had twenty the that's four of including million the That's cash [Indiscernible] last million in activities. point to utilization, operating two point Also of that during of was that tranches generated the thirty four euro, six financing agreement cash two million forty

the next recent most work the seventeen, with slide, our to financing Moving on initiatives.

at ADS’, utilizes point seven on placement we with and financing ADS remember healthcare OCABSA twenty several year, foreign reduced includes year, per nine point if also percent has QX next seventy with zero agreements. our that's and two extended zero to April Depositary two. direct registered point American price nine Shares euro twenty dollars This XX:XX extended euro with direct QX [Indiscernible] five this two of investors, two tranches dollars of six You five one called announced focused cash five horizon further company the and possibly institutional financing that horizon with accredited further the per the zero coverage. to what’s the the that's twenty associated seven The QX OCABSA share. This the twenty date cash to associated

filing the X in and milestones course, before cancer regulatory and course, of for line expect XX:XX summarize top in the twenty of determination of and QX line then cancer, Dose have X of pancreatic as towards first-line session. results you you eryaspase the also, Finally, we like that's I cancer, would we two. year. BLA questions year, one. be of in will pancreatic the to top second-line here you BLA the the finding one in respect that, XX:XX the we the in upcoming for hypersensitive Phase With the end moving call patients. your now first potential eighteen. Again, That's expected XX:XX thank Phase pancreatic any next percent to we'll TRYbeCAX may the filing XX:XX Q before in attention, will TRYbeCAX Tolerable the to half to Again, Iman, phase for in trial limits A course, we'll top start the by assuming MTD, potentially twenty the repeating already data open and twenty of have. for I and trial the and have myself subject patients reminding in of following that trial ask the the end the explained looking would also the Language]. like of look those of TRYbeCA-X, want ALL French current price now before of the And BLA to before to year. very potential forward Of ongoing eryaspase of so. forward end key of market course the also twenty also the you do I to quickly year, Also dose Operator, dilution. to incorrect half the next [Foreign breast results over that's of Maximum you. eryaspase the the in from question to welcome any that’s trial are soon cancer of quite and the for slide, of first results We

XX:XX [Operator with Peaker Instructions] We have Cowen. a question from Boris

XX:XX Good hear me? morning. you Can

Good are you? XX:XX How morning. Yes, Boris.

pivotal you? patient study XX:XX terms How are differences? in Good. X enrollment to other cancer pancreatic as well does follow-up of up that how characteristics care or geography, of age, any your in Phase is, kind any Question as the comes frequently compare the

answer. XX:XX I’ll Iman this leave to to

XX:XX Hi, morning, Boris. Good

and trial is difference. and are The Europe don’t our highly we impact highest the is, preferences, who inclusion, just So Phase criteria. that States. overall Phase believe to trial the Spain. is compared going of enrolling any have a two So which the there geographic two with France what exclusion trial to Phase the similar to to difference country but the three in followed trial XX:XX these naturally on study, in the United phase [Indiscernible] is because remains trial have here is patient one we the

So would you percent first-line, patient mind, what the trial, for going if fixed, remember, two ninety Phase to is be compared If almost in two-thirds is [Indiscernible] to percent. [Indiscernible] would version, in our the what XX:XX to expecting have we patient second-line so receiving patients achieved that actually, line of we to the in the phase be the still and be in or with that probably the in that’s FOLFIRINOX [asparagine] just therapy three second (ph) difference. also one-third trial ninety more

We in a either two is difference of progression same. that of eryaspase status also combination terms and make we have It really Hidalgo. view, Professor view will backbone that's our chemotherapy in the from actually don't same of believe ours confirms which much the in activity some of criteria inclusion, strategy, with many choices. But the other first-line is for you XX:XX the otherwise performance same, is of the course virtually know and the exclusion

XX:XX very Great. much for we all Thanks big reveal. my Well, and you data taking to thank question. the look forward

you, Boris. XX:XX Thank

XX:XX questions at showing And this I'm not further any time.

XX:XX I been clear. think if very must question no then, further think we I have

attention, I want your to in And quarter the as next to it's data Boris forward for continued And for now come. you indeed thank support. to the your said, so, looking all

bye. keep all. obviously posted Bye, Europe. we the in as you, meantime, day always. we'll wish Care. So, you Take great In great you afternoon Thank a and

participating. call. This today's for conference you XX:XX Thank concludes

You may now disconnect.